Sodium-selenite

Phase 3Small molecule

SStanford University

Sodium-selenite is one of 134 small molecule programs targeting Cardiac Arrest. It is currently in Phase 3.

Indications

Total Trials

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac ArrestActive, not recruiting

ToxicityActive, not recruiting

SepsisActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Cardiac ArrestPhase 2

Active, not recruiting

ToxicityPhase 3

Active, not recruiting

SepsisPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Sodium-selenite

SStanford University

Phase 3

1 2

Avastin

Voltaren

1 4

Chirocaine

PPurdue Pharma LP

Preclinical

1 5

Vfend

PPrism Pharmaceuticals

Preclinical

—6

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 7

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 8

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 9

Recombinant Human Chorionic Gonadotropin

Merck & Co.

Preclinical

1 10

Iniparib

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiac Surgery1 trial

SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial).

Unknown status·—·Phase 3·NCT02002247·1,400 enrolled

Sepsis1 trial

Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis

Completed·KKompetenznetz Sepsis·Phase 3·NCT00832039·1,089 enrolled

Cardiac Arrest1 trial

Selenium to Improve Neurological Outcome After Cardiac Arrest

Withdrawn·MMedical University of Graz·Phase 2·NCT01390506

Toxicity1 trial

Selenium in the Treatment of Arsenic Toxicity and Cancers

Completed·TTexas Tech University·Phase 3·NCT01442727·819 enrolled

Metastatic Cancer1 trial

Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer

Completed·SStanford University·Phase 1·NCT02184533·15 enrolled

3 more indications

Breast Cancer1 trial

The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00188604·34 enrolled

Prostate Cancer1 trial

Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone

Withdrawn·SStanford University·Phase 1·NCT04296578

Carcinoma1 trial

Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma

Unknown status·KKarolinska University Hospital·Phase 1/2·NCT01959438·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Sodium-selenite. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodium-selenite compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sodium-selenite. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SStanford University

Sodium-selenite

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiac Surgery1 trial

Sepsis1 trial

Cardiac Arrest1 trial

Toxicity1 trial

Metastatic Cancer1 trial

Breast Cancer1 trial

Prostate Cancer1 trial

Carcinoma1 trial

References

Drug Info

Quick Facts

Related News